I
diopathic pulmonary arterial hypertension (IPAH) is a highly morbid disease characterized by progressive obliteration of precapillary arterioles and a contemporary survival time after diagnosis of slightly more than 5 years (1) . A small subset (5% to 10%) of patients with IPAH displays dramatic hemodynamic improvement in response to acute exposure to pulmonary vasodilators, and approximately one half of these "vasodilator-responsive" patients improve clinically with calcium-channel blocker therapy (2) . The disparity in outcomes has fueled speculation for decades that vasodilator-responsive and nonresponsive IPAH are distinct diseases.
Idiopathic pulmonary arterial hypertension is believed to arise from pulmonary vascular remodeling, with vasoconstriction providing a potentially small contribution. The limited decrease in pulmonary vascular resistance with treatment of IPAH and pathologic studies showing vascular remodeling and plexiform lesions support this theory. But does it apply to the subset of patients with IPAH who respond to vasodilators? Pathologic studies in patients with IPAH have not used contemporary criteria to define the vasodilator-responsive subtype. Although 1 study examined the relationship between histologic findings and response to vasodilators (3), we lack specimens to compare the pathology of responders and nonresponders because of the excellent survival rate of the former group. The marked decrease in mean pulmonary arterial pressure (mPAP) and pulmonary vascular resistance with acute vasodilator administration, however, argues against an irreversible pulmonary vascular pathology.
Research rarely warrants publication based on findings in only 2 patients. Such work must necessarily show a new discovery or unveil a previously unknown aspect of a disease. In this issue, Langleben and colleagues (4) meet both criteria for vasodilatorresponsive IPAH. Applying a technique to measure endothelial functional capillary surface area (FCSA), the authors, to our knowledge, present the strongest evidence to date that vasodilator-responsive IPAH is characterized by immediately reversible vasoconstriction, whereas nonresponsive IPAH involves irreversible vascular obliteration. Although pathologic material would be required to definitively assess whether and what morphologic derangements are present, Langleben and colleagues' study infers that responders have little, if any, luminal obstruction.
The authors measured FCSA in responders and nonresponders before and after vasodilator infusion by using a clever technique that leverages the capacity of the pulmonary capillary endothelium to metabolize angiotensin. Greater angiotensin metabolism indicates greater pulmonary FCSA. Metabolism across the pulmonary circulation was determined with a synthetic and highly specific substrate for pulmonary capillary, endothelium-bound, angiotensin-converting enzyme ( 3 H-Benzoyl-Phe-Ala-Pro [BPAP]) (5, 6) . If vasoconstriction drives elevated pulmonary vascular resistance and mPAP in IPAH, FCSA would increase after exposure to a vasodilator through recruitment of microvasculature. Conversely, if precapillary microvascular obstruction causes IPAH, the vasculature would be unable to recruit additional capillaries, resulting in no change in FCSA.
The combination of baseline hemodynamics and BPAP metabolism in response to a vasodilator challenge revealed 2 distinct phenotypes. Nonresponders had worse hemodynamics and lower resting FCSA at baseline than responders. Their mean cardiac output increased 36% after epoprostenol administration, but BPAP metabolism decreased and calculated FCSA remained unchanged. This finding indicates that augmented flow was not associated with recruitment of additional microvasculature. Responders, by contrast, exhibited a substantial decrease in mPAP and increase in cardiac output, no change in BPAP metabolism, and an increase in FCSA. Therefore, increased flow in responders was matched by increased exposure to pulmonary capillary, endothelium-bound, angiotensinconverting enzyme in newly recruited microvasculature.
In addition to providing physiologic evidence that vasoconstriction is the primary mediator of pulmonary hypertension in responders, Langleben and colleagues' study draws attention to the importance of careful, detailed phenotypic studies of common and rare diseases. That some patients with IPAH respond well to calcium-channel blocker therapy was observed more than 20 years ago (7) . What mediates vasodilation in these patients and differs in nonresponders remains unknown.
This study is the first step toward proving that this subphenotype differs physiologically and suggests important next steps. Specifically, the molecular cause of vasodilator-responsive IPAH requires studies to define vasoconstrictive mechanisms and determine whether they can be manipulated to improve therapy and outcomes in the much larger group of nonresponders. Recent work from our group shows that the peripheral blood transcriptomic pattern in responders differs from that of nonresponders (8) . Whether this subphenotype has a genetic predisposition or these types of responses can be identified in other groups of "out-ofproportion" pulmonary hypertension, such as that seen in hypoxia, is unknown. Answers to these questions hold promise of improved care for all patients with pulmonary hypertension, showing how phenotyping in a rare subset can have an impact far beyond those 2 patients.
Aside from the small sample size, an important study limitation is the inability to explain why cardiac output increased in nonresponders in the absence of microvascular recruitment. One potential explanation is EDITORIAL Annals of Internal Medicine that epoprostenol increased right ventricular contractility, as seen in prior studies (9) . Correlating BPAP metabolism with histopathology lacking luminal obstruction would be definitive, but the dearth of responders and their excellent survival rates make pathologic studies difficult.
Overall, this study makes an important scientific contribution to our understanding of the pathobiology of IPAH and, as the authors propose, suggests that these 2 hemodynamic phenotypes may represent pathologically distinct diseases. It addresses the ageold question of what drives elevated mPAP in IPAH: vascular remodeling or vasoconstriction? The answer is pleasing to both sides of the argument-it depends on the type of IPAH. The task before us is to use this information to improve identification and treatment for the largest group of patients with IPAH: those without a marked response to vasodilators.
